Similar findings have been observed in a mouse model of non-small cell lung cancer (NSCLC), in which FAK inhibition renders this immunologically “cold” tumor responsive to immune checkpoint inhibition through a decrease in fibrosis and increase in effector T cell infiltration [70]. Here, PTK2 is linked to non-small cell lung carcinoma.